RxDoctor Payments Data

Frank Flautt, MD

Internal Medicine · Greenwood, MSNPI 1760553655

Payments from drug & device makers

$2,586in general payments, 2019–2025

Across 149 payments — averaging $17.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$526
  • Lilly USA, LLC$352
  • Pfizer$324
  • Novo Nordisk$265
  • Abbott$260
  • GSK$239
  • plus $619 from 13 others

What the payments were for

  • Food & beverage$2,586100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,586 in reported general payments places this provider in the 75th percentile of 846 internal medicine providers in Mississippi.

See all internal medicine providers in Mississippi

Medicare billing

Part B allowed, 2024
$129,970
Medicare patients
385
Services billed
3,291

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban156$103,195
OzempicSemaglutide51$53,067
MounjaroTirzepatide37$50,259
EntrestoSacubitril/Valsartan33$27,276
XareltoRivaroxaban32$24,703
FarxigaDapagliflozin Propanediol35$23,027
JardianceEmpagliflozin35$20,750
RybelsusSemaglutide11$17,671
JanuviaSitagliptin Phosphate24$12,362
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$10,740
LinzessLinaclotide15$9,878
Tresiba Flextouch U-200Insulin Degludec17$9,396
BrilintaTicagrelor13$7,272
MyrbetriqMirabegron11$6,673
JentaduetoLinagliptin/Metformin Hcl13$5,618

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$324$106,054170 claims
Novo NordiskOzempic, Rybelsus$265$70,73862 claims
Lilly USA, LLCMounjaro$352$50,25937 claims
AstraZenecaFarxiga, Brilinta$526$30,29948 claims
NovartisEntresto$160$27,27633 claims
Boehringer IngelheimJardiance, Jentadueto$40$26,36848 claims
Johnson & JohnsonXarelto$41$24,70332 claims
AbbVieLinzess, Synthroid$132$14,04467 claims
MerckJanuvia$16$12,36224 claims
GSKTrelegy Ellipta$239$10,74017 claims
Astellas Pharma US IncMyrbetriq$31$6,67311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 846 internal medicine providers in Mississippi.

Other internal medicine in Greenwood

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →